CompsDesk

HEPION PHARMACEUTICALS, INC. (HEPA) — benchmarks from SEC filings

Latest fiscal year 2023 · computed deterministically from XBRL 10-K data · coverage 100%

$0MRevenue FY2023

n/aRevenue growth

n/aOperating margin

n/aNet margin

n/aFCF margin

In fiscal 2023, HEPION PHARMACEUTICALS, INC. reported revenue of $0M. Operating margin was n/a and net margin n/a, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from HEPA's SEC XBRL 10-K filing — deterministic, with no estimates.

Fiscal year	Revenue	Op margin	Net margin
FY2023	$0M	n/a	n/a
FY2022	$0M	n/a	n/a
FY2021	$0M	n/a	n/a
FY2020	$0M	n/a	n/a

How does HEPA compare against its actual peer set?

A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.

See subscription plans → or see a free sample first

Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.